Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Pfizer Backs Out Of Heart-Disease Deal, Leaving Ionis Stock To Crumble
02:27pm, Monday, 31'st Jan 2022 Investor''s Business Daily
Pfizer backed out of a deal to co-develop an Ionis Pharmaceuticals heart-disease drug on Monday, leading IONS stock to crumble.
Why Are Ionis Pharmaceuticals Shares Tanking Today?
02:00pm, Monday, 31'st Jan 2022 Benzinga
Pfizer Inc (NYSE: PFE ) and Ionis Pharmaceuticals Inc (NASDAQ: IONS ) will discontinue the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy. A little over two years after Pfizer paid Ionis $250 million cash to in-license rights to vupanorsen (AKCEA-ANGPTL3-LRx), now the pharma giant has decided to ax late-stage Full story available on Benzinga.com
Ionis stock falls after discontinuing Pfizer-led vupanorsen program (NASDAQ:IONS)
01:00pm, Monday, 31'st Jan 2022 Seeking Alpha
Ionis Pharmaceuticals (IONS) down 9.2% premarket after discontinuing the Pfizer (PFE)-led clinical development program for vupanorsen (PF-07285557), an investigational antisense
Ionis, Pfizer scrap plans for experimental cardiovascular drug
07:41am, Monday, 31'st Jan 2022
Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they discontinued a program testing an experimental treatm
Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA
05:33pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA
01:54pm, Tuesday, 25'th Jan 2022
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Ionis'' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
02:25pm, Monday, 24'th Jan 2022 Benzinga
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc''s (NASDAQ: IONS ) eplontersen, an investigational antisense medicine for transthyretin-mediated amyloidosis. Eplontersen is currently in Phase 3 trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN). It is designed to … Full story available on Benzinga.com
Ionis'' eplontersen an Orphan Drug in U.S. for transthyretin-mediated amyloidosis
12:14pm, Monday, 24'th Jan 2022 Seeking Alpha
Ionis Pharmaceuticals (IONS) announces that the FDA has granted Orphan Drug Designation to eplontersen, an investigational antisense medicine for the treatment of people living
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
09:25am, Monday, 24'th Jan 2022
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for transthyretin-mediated amyloidosis. Eplontersen is
Ionis' (IONS) Partner to Begin New Huntington's Disease Study
10:46am, Tuesday, 18'th Jan 2022
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
09:32pm, Friday, 14'th Jan 2022 Benzinga
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With the funds falling over the past year and hitting new lows, Benzinga asked w
3 Biotech Stocks Wall Street Thinks Could Soar 50% or More in 2022
12:01pm, Friday, 14'th Jan 2022 The Motley Fool
The analysts might be overly optimistic in some cases, though.
3 Biotech Stocks Wall Street Thinks Could Soar 50% or More in 2022
07:01am, Friday, 14'th Jan 2022
The analysts might be overly optimistic in some cases, though.
AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate
04:15pm, Monday, 10'th Jan 2022 Zacks Investment Research
AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
04:20pm, Wednesday, 05'th Jan 2022 Zacks Investment Research
Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.
